Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| GH Research PLCORDINARY SHARES | ORDINARY SHARES | $357M | 41.2% |
| Cullinan Therapeutics Inc.COM | COM | $163M | 18.9% |
| Stoke Therapeutics Inc.COM | COM | $132M | 15.3% |
| Agios Pharmaceuticals Inc.COM | COM | $127M | 14.6% |
| C4 Therapeutics Inc.COM STK | COM STK | $34.2M | 4.0% |
| Korro Bio Inc.COM | COM | $20.3M | 2.3% |
| Tscan Therapeutics Inc.COM | COM | $7.86M | 0.9% |
| Precision Biosciences Inc.COM NEW | COM NEW | $7.47M | 0.9% |
| Neuphoria Therapeutics Inc.COM | COM | $3.83M | 0.4% |
| Passage Bio Inc.COM NEW | COM NEW | $3.29M | 0.4% |
| CG Oncology Inc.COM | COM | $2.23M | 0.3% |
| Pliant Therapeutics Inc.COM | COM | $2.05M | 0.2% |
| Entrada Therapeutics Inc.COM | COM | $1.31M | 0.2% |
| Vyne Therapeutics Inc.COM | COM | $1.06M | 0.1% |
| Proqr Thrapeutics N VSHS EURO | SHS EURO | $970K | 0.1% |
| Traws Pharma Inc.COM NEW | COM NEW | $472K | 0.1% |
| Foghorn Therapeutics Inc.COM | COM | $301K | 0.0% |
| Denali Therapeutics Inc.COM | COM | $300K | 0.0% |
| Xencor Inc.COM | COM | $293K | 0.0% |
| Absci CorporationCOM | COM | $246K | 0.0% |
| Werewolf Therapeutics Inc.COM | COM | $237K | 0.0% |
| Immatics N.vSHS | SHS | $235K | 0.0% |
| Avalo Therapeutics Inc.COM NEW | COM NEW | $187K | 0.0% |
| Bolt Biotherapeutics Inc.COM NEW | COM NEW | $119K | 0.0% |
| Nuvation Bio Inc.COM CL A | COM CL A | $91K | 0.0% |
| Eupraxia Pharmaceuticals Inc.COM | COM | $66.1K | 0.0% |
| Inhibikase Therapeutics Inc.COM NEW | COM NEW | $40.6K | 0.0% |
- Class
- ORDINARY SHARES
- Share
- 41.2%
- Class
- COM
- Share
- 18.9%
- Class
- COM
- Share
- 15.3%
- Class
- COM
- Share
- 14.6%
- Class
- COM STK
- Share
- 4.0%
- Class
- COM
- Share
- 2.3%
- Class
- COM
- Share
- 0.9%
- Class
- COM NEW
- Share
- 0.9%
- Class
- COM
- Share
- 0.4%
- Class
- COM NEW
- Share
- 0.4%
- Class
- COM
- Share
- 0.3%
- Class
- COM
- Share
- 0.2%
- Class
- COM
- Share
- 0.2%
- Class
- COM
- Share
- 0.1%
- Class
- SHS EURO
- Share
- 0.1%
- Class
- COM NEW
- Share
- 0.1%
- Class
- COM
- Share
- 0.0%
- Class
- COM
- Share
- 0.0%
- Class
- COM
- Share
- 0.0%
- Class
- COM
- Share
- 0.0%
- Class
- COM
- Share
- 0.0%
- Class
- SHS
- Share
- 0.0%
- Class
- COM NEW
- Share
- 0.0%
- Class
- COM NEW
- Share
- 0.0%
- Class
- COM CL A
- Share
- 0.0%
- Class
- COM
- Share
- 0.0%
- Class
- COM NEW
- Share
- 0.0%
The share class is shown on a wider screen.
The 27 largest of 27 positions by value, with holdings of the same security combined. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 1910456
- File number
- 028-22151
- Options
- 0 call, 0 put
- In the 25 largest
- 100.0%
- Prior quarter
- $633M at 31 March 2026
- Positions opened
- 6
- Positions closed
- 2
Common questions
What are Lynx1 Capital Management’s 13F holdings worth?
$866 million across 27 positions for the quarter ended 30 June 2026.
What is Lynx1 Capital Management’s largest 13F holding?
GH RESEARCH PLC (ORDINARY SHARES) was the largest position at $357 million, or 41.2% of reported 13F value, as of 30 June 2026.
How concentrated is Lynx1 Capital Management’s 13F portfolio?
The ten largest positions accounted for 98.8% of reported value and the twenty-five largest for 100.0%, across 27 positions as of 30 June 2026.
Does Form 13F show everything Lynx1 Capital Management manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Lynx1 Capital Management file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.